G2GBIO Inc.

456160 · KQ · Healthcare / Biotechnology

34,900.00KRW-1200.00 (-3.32%)

Price History

Full chart

Market Stats

Previous Close36,100.00

Open35,500.00

Day Range34,250.00 – 38,300.00

52-Week Range22,400.00 – 124,000.00

Volume231.93K

Market Cap721.38B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

50-Day Avg35,997.00

200-Day Avg61,078.00

About

G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company's pipeline products include GB-5001, GB-5001A, and GB-5112 for the treatment of Alzheimer's disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal castration; and GB-2006, an animal postoperative pain relief drug, which is in clinical trial stage. The company was founded in 2017 and is headquartered in Cheongju-si, South Korea.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Hee-yong Lee Ph.D.
Headquarters21, Uiryodanji-gil, Cheongju-si, South Korea, Korea
Websitehttps://www.g2gbio.com

Leadership

Mr. Hee-yong Lee Ph.D.CEO & Director · b. 1965
Mr. GyoJoong JeonPresident, CFO, Head of Business Management Division & Director · b. 1974
Mr. Eunyoung SeolVP, Head of R&D and Director · b. 1969
Mr. YongJin LeeVP, Head of Clinical & Development Division and Director · b. 1965
Mr. JuHan LeeHead of Global Business Strategy Division · b. 1978
Dr. Mark Tracy Ph.D.President of Tracy BioConsulting LLC

Financials

Income Statement

Currency: KRW	2024-12-31	2025-12-31
Total Revenue	768.93M	423.07M
Growth (%)	-	-44.98%
Cost of Revenue	578.60M	456.55M
Gross Profit	190.33M	-33.48M
Gross Margin	24.75%	-7.91%
Operating Expense	10.95B	12.17B
Operating Income	-10.76B	-12.20B
Operating Margin	-1399.80%	-2884.22%
EBITDA	-78.98B	-9.78B
EBITDA Margin	-10271.04%	-2311.60%
Net Income	-83.25B	-12.09B
Net Income Margin	-10827.32%	-2857.07%
R&D	7.67B	8.09B
R&D as % of Total Revenue	997.01%	1911.48%
Interest Expense	2.44B	707.13M
Interest Expense % of Total Revenue	317.82%	167.14%

Balance Sheet

Currency: KRW	2024-12-31	2025-12-31
Total Assets	25.35B	67.75B
Total Liabilities	144.88B	9.41B
Total Equity	-119.54B	58.34B
Cash	10.02B	7.98B
Net Debt	4.56B	-

Cash Flow

Currency: KRW	2024-12-31	2025-12-31
Operating Cash Flow	-7.97B	-13.92B
Capital Expenditure	583.75M	323.97M
Free Cash Flow	-8.55B	-14.25B
FCF to OCF	107.33%	102.33%

Earnings

Report Date	Sep 30, 2025	Dec 31, 2025	Jun 30, 2026
EPS Estimate	-	-	-
EPS Actual	-237.56	-170.67	-344.20
Surprise	-	-	-
Timing	-	-	-

Key Statistics & Ratios

Market Cap721.38B

Enterprise Value356.37B

Trailing P/E0.00

Forward P/E0.00

Price / Sales52.86

Price / Book3.83

Revenue (TTM)0

Gross Profit (TTM)0

Profit Margin0.00%

Operating Margin0.00%

Return on Equity0.00%

Return on Assets0.00%

Shares Outstanding16.55M

Shares Float0

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Nov 5, 20253:1